HDAC4 Inhibitors as Antivascular Senescence Therapeutics. (29th June 2022)

• Record Type: Journal Article
• Authors: Huang, Chuoji; Lin, Zhongxiao; Liu, Xiaoyan; Ding, Qian; Cai, Jianghong; Zhang, Zhongyi; Rose, Peter; Zhu, Yi Zhun
• Other Names: Georgieva Milena Academic Editor.
• Is Part Of: Oxidative medicine and cellular longevity. Volume 2022(2022)
• Publication Date: 2022-06-29
• Subjects: Oxidative stress -- Periodicals; Cells -- Aging -- Periodicals; Cells -- Aging; Oxidative stress; Oxidative Stress -- Periodicals; Cell Aging -- Periodicals; Periodicals; 611.0181
• DOI: 10.1155/2022/3087916
• Languages: English
• ISSNs: 1942-0900

Abstract

Abstract : Aging is an inevitable consequence of life, and during this process, the epigenetic landscape changes and reactive oxygen species (ROS) accumulation increases. Inevitably, these changes are common in many age-related diseases, including neurodegeneration, hypertension, and cardiovascular diseases. In the current research, histone deacetylation 4 (HDAC4) was studied as a potential therapeutic target in vascular senescence. HDAC4 is a specific class II histone deacetylation protein that participates in epigenetic modifications and deacetylation of heat shock proteins and various transcription factors. There is increasing evidence to support that HDAC4 is a potential therapeutic target, and developments in the synthesis and testing of HDAC4 inhibitors are now gaining interest from academia and the pharmaceutical industry.